Gniadek and colleagues evaluated PD-L1 expression on tissue microarrays from 150 NSCLC cases (71 adenocarcinomas and 79 squamous cell carcinomas) using SP142 antibody (Spring Bioscience, Pleasanton, CA) and Abcam detection kit: at ≥ 1% cutoff, 47% of cases were positive while at ≥ 50% cutoff they found positivity in 24% of cases. This evidence concerns the gene CD274 and squamous cell carcinoma.